6543results about How to "Reduce accumulation" patented technology

This invention is directed to an improved method for preventing deposition residue buildup on the internal surfaces of an ALD reactor chamber. In an ALD deposition process, the surfaces of a substrate are treated with an initiating precursor generating a labile atom reactive with a deposition precursor. Excess initiating precursor is removed from the reactor and the substrate surface then is exposed to a deposition precursor reactive with the labile atom under conditions for generating a fugitive reaction product containing the labile atom and leaving a deposition product. The process is repeated generating alternate layers of initiation and deposition precursor reaction products. The improvement in the ALD process resides in passivating the internal surfaces of the reactor by removing labile atoms reactable with either the initiating or deposition precursors prior to effecting ALD deposition.

A method of making a tissue-derived implantable medical device that includes contacting the tissue with a composition comprising at least one oxidizing agent prior to implantation of the medical device.

A silicon electrode for a plasma reaction chamber wherein processing of a semiconductor substrate such as a single wafer can be carried out and a method of processing a semiconductor substrate with the electrode. The electrode is a low resistivity electrode having an electrical resistivity of less than 1 ohm-cm. The electrode can be a zero defect single crystal silicon or silicon carbide electrode such as a showerhead electrode bonded or clamped to support such as a temperature controlled plate or ring. The showerhead electrode can be in the form of a circular disk of uniform thickness and an elastomeric joint can be provided between a support ring and the electrode. The electrode can include gas outlets having 0.020 to 0.030 inch diameters.

Provided are nanoparticles and formulations which are useful for cosmetic, diagnostic and therapeutic applications to mammals such as humans.

A gas separation process uses a structured particulate bed of adsorbent coated shapes/particles laid down in the bed in an ordered manner to simulate a monolith by providing longitudinally extensive gas passages by which the gas mixture to be separated can access the adsorbent material along the length of the particles. The particles can be laid down either directly in the bed or in locally structured packages/bundles which themselves are similarly oriented such that the bed particles behave similarly to a monolith but without at least some disadvantages. The adsorbent particles can be formed with a solid, non-porous core with the adsorbent formed as a thin, adherent coating on the exposed exterior surface. Particles may be formed as cylinders/hollow shapes to provide ready access to the adsorbent. The separation may be operated as a kinetic or equilibrium controlled process.

An ophthalmic pharmaceutical composition useful in the treatment of glaucoma and control of intraocular pressure comprising an effective amount of a selective modulator of ALK5 receptor activity is disclosed. Also disclosed is a method of treating glaucoma and controlling intraocular pressure comprising applying a therapeutically effective amount of a pharmaceutical composition comprising a selective modulator of ALK5 receptor activity to an affected eye of a patient.

Provided herein are methods of treating or ameliorating a pediatric cholestatic liver disease by non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a pediatric liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an ASBTI or a pharmaceutically acceptable salt thereof.

The invention relates to an agrobacterium strain (Agrobacterium sp.) with heterotrophic nitrification-aerobic denitrification capability and an application thereof in nitrogenous effluent treatment. The bacterial strain is characterized in that: 16S rRNA gene contains nucleotide sequence shown in sequence table with a sequence length of 1418bp and a accession number FJ639330 in Genbank. The preservation number thereof is CGMCC No.2962. The agrobacterium of the invention has not only heterotrophic nitrification capability but also aerobic denitrification capability. During nitrogenous effluent treatment, and one aerobic phase can cause ammonian to change into gaseous product with high denitrification efficiency and easy operation and tremendous economic benefit compared with the traditional biological denitrification process.

A creping aid system for use on a creping cylinder, for example, a Yankee dryer, comprises a creping adhesive and a creping modifier, the combination comprising polyethylene.

The present invention relates to findings that reducing the activity of Plasminogen Activator Inhibitor-1 (PAI-1) suppresses an excessive deposition of collagen which is known as a cause for the formation of abnormal scars. These abnormal scars include but are not limited to keloids, adhesions, hypertrophic scars, skin disfiguring conditions, fibrosis, fibrocystic conditions, contractures, and scleroderma, all of which are associated with or caused by an excessive deposit of collagen in a wound healing process. Accordingly, aspects of the present invention are directed to the reduction of PAI-1 activity to decrease an excessive accumulation of collagen, prevent the formation of an abnormal scar, and/or treat abnormal scars that result from an excessive accumulation of collagen. The PAI-1 activity can be reduced by PAI-1 inhibitors which include but are not limited to PAI-1 neutralizing antibodies, diketopiperazine based compounds, tetramic acid based compounds, hydroxyquinolinone based compounds, Enalapril, Eprosartan, Troglitazone, Vitamin C, Vitamin E, Mifepristone (RU486), and Spironolactone to name a few. Another aspect of the present invention is directed to methods of measuring PAI-1 activity in a wound healing process and determining the propensity of the formation of an abnormal scar.

A process and an apparatus for the manufacture of biogas and a solids fraction from an organic waste feedstock is provided. The process involves thermal hydrolysis of the organic waste feedstock at a temperature from about 100 to about 220° C., a pressure from about 5 to about 20 bars, for a period of time from about 15 minutes to 4 hours, to produce a hydrolysate. The hydrolysate undergoes anaerobic digestion at a temperature from about 25 to 60° C., for a period of time from about 1 to 35 days to produce a biogas stream and a digestate. The digestate is separated into a solids fraction and a liquid fraction, and a portion of the solids fraction is recycled for further anaerobic digestion. The biogas stream, characterized as having a methane content from between 55 to 80% by volume, and the solids fraction, are recovered. The apparatus includes a receiving bin for receiving and supplying organic waste feedstock to a thermal hydrolysis reactor. The thermal hydrolysis reactor for processing the organic waste feedstock at a temperature from about 100 to about 220° C., a pressure from about 5 to about 20 bars, for a period of time from about 15 minutes to 4 hours to produce a hydrolysate. An anaerobic digester for processing the hydrolysate at a temperature from about 25 to 60° C., for a period of time from about 1 to 35 days to produce the biogas and a digestate, and a solids thickening tank for separating the digestate into the solid fraction, a liquid fraction and a secondary biogas fraction.

The invention provides compositions comprising an effective amount of an agent that inhibits a BET protein (e.g., Brd2, Brd3, Brd4), and methods of using such compositions for treating or preventing metabolic syndrome, obesity, type II diabetes, insulin resistance, and related disorders characterized by undesirable alterations in metabolism or fat accumulation.

The invention discloses a rotating-type grain distributor and a granary provided with the grain distributor, and belongs to the technical field of granaries. The rotating-type grain distributor comprises a grain collecting barrel. The grain collecting barrel comprises a barrel wall and a barrel bottom. The outer side of the barrel wall of the grain collecting barrel is provided with two downward-inclined grain sliding pipes. The bottom face and one side face of each grain sliding pipe are curved surfaces which are of an integral structure. When the rotating-type grain distributor is used, the rotating-type grain distributor is arranged at a grain inlet of the granary, after grain enters the grain collecting barrel, the grain flows into the grain sliding pipes, and when the rotating-type grain distributor rotates, the grain sliding pipes rotate along with the rotating-type grain distributor. Due to the fact that the bottom face and one side face of each grain sliding pipe are curved surfaces which are of the integral structure, when the rotating-type grain distributor rotates, under the effect of centrifugal force and tangential force generated by the curved surfaces, the grain is scattered and flows out of the grain sliding pipes, and the grain falls onto a circular cross section of the granary. According to the rotating-type grain distributor, the impurity accumulation caused by automatic grading formed by concentrated falling of the grain is alleviated, and the safe storage of the grain is guaranteed.

Compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudoobstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders as well as other conditions and disorders are described. The compositions feature peptides that activate the guanylate cyclase C (GC-C) receptor.

At least one exemplary embodiment that is directed to a conformal hearing aid comprising: a hearing aid body, where the hearing aid body houses a microphone and a receiver, where the microphone is positioned within the hearing aid body to measure acoustic signals from an ambient environment, and where the receiver is positioned within the hearing aid body to emit acoustic signals toward a tympanic membrane of a user; an expandable element, where the expandable element is operatively connected to the hearing aid body, and where the expandable element is configured to encompass a circumferential portion of the hearing aid body when expanded; and an inflation management system, where the inflation management system is configured to expand the expandable element when actuated.

Filters for EUV lithography, methods of manufacture thereof, and methods of filtering in an EUV lithography system are disclosed. The filter comprises a nanotube material layer sandwiched by two thin material layers that are highly transmissive and provide structural support for the nanotube material layer. The filter is supported on at least one side by a patterned structural support. The filter mitigates debris, provides spectral purity filtering, or both.